Kyowa Kirin is continuing to monitor the COVID-19 outbreak. Learn More
In the MAVORIC clinical trial of previously treated MF and SS patients, POTELIGEO delayed median PFS 7.6 months compared with 3.1 months in vorinostat-treated patients.
PFS was evaluated using global composite response criteria across 4 disease compartments (skin, blood, lymph nodes, and viscera). For PFS to be considered, progression had to be absent from all 4 disease compartments.
Important Safety Information